Actionable Clinical Features and Biomarkers to Facilitate the Management of Irritable Bowel Syndrome
- 19 November 2025
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1094-1100
Abstract
Irritable bowel syndrome (IBS) is a common, chronic disorder of gut-brain interaction that is characterized by core clinical features of abdominal pain and altered bowel movements. Because IBS remains defined by symptom patterns, most clinical care for patients with IBS relies on treatments directed by IBS subtype. Although the biopsychosocial model has advanced disorder of gut-brain interaction research and clinical care, and the current Rome IV criteria have greatly helped the diagnostic paradigm for IBS, the model does not identify specific pathophysiological mechanisms that operate in any one patient. Consequently, most interventions for IBS benefit only subsets of patients, and patients often progress through a series of trial and error approaches to manage their IBS symptoms. There is a major clinical need to develop a practical basis for a personalized medicine approach in IBS care. In this article, we discuss how clinicians may incorporate additional clinical features and actionable biomarkers to better inform the initial choice of therapy for patients with IBS. Ideally, such a mechanistic approach should be more efficient, and ultimately more effective, leading to improved patient satisfaction and clinical outcomes.Keywords
This publication has 90 references indexed in Scilit:
- Biomarkers in Patients with IBS: Continue the Grail Quest or Give It a Rest?Digestive Diseases and Sciences, 2025
- Intestinal Disaccharidase Deficiency in Adults: Evaluation and TreatmentCurrent Gastroenterology Reports, 2023
- Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and MotilityUnited European Gastroenterology Journal, 2022
- Overlap between irritable bowel syndrome and hypermobileEhlers–Danlossyndrome: An unexplored clinical phenotype?American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2021
- The gastrointestinal symptoms present in patients with postural tachycardia syndrome: A review of the literature and overview of treatmentAutonomic Neuroscience, 2018
- Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel SyndromeDigestive Diseases and Sciences, 2017
- Vinculin in cell–cell and cell–matrix adhesionsCellular and Molecular Life Sciences, 2017
- Bowel Functions, Fecal Unconjugated Primary and Secondary Bile Acids, and Colonic Transit in Patients With Irritable Bowel SyndromeClinical Gastroenterology and Hepatology, 2013
- Pilot study of pyridostigmine in constipated patients with autonomic neuropathyClinical Autonomic Research, 2008
- Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and TherapeuticsCellular and Molecular Life Sciences, 2008